Patent application number | Description | Published |
20160046414 | DRIZZLE SAFETY SEAL AND METHODS OF USE - A container having an opening, a first seal covering the container opening, the first seal having an aperture or passageway positioned therein, a second seal to close off the aperture, and, thus, when such second seal is removed functions to provide reduced or restricted pouring capacity of the container contents via said aperture in the first seal. | 02-18-2016 |
20160046422 | RIM TABBED DRIZZLE SAFETY SEAL AND METHODS OF USE - A container having an opening, a first seal covering the container opening, the first seal having an aperture or passageway positioned therein and proximate a periphery edge, a second seal hingedly affixed thereto said first seal proximate said periphery to close off the aperture, and, thus, when such second seal is removed functions to provide reduced or restricted pouring capacity of the container contents via said aperture in the first seal. | 02-18-2016 |
Patent application number | Description | Published |
20130052192 | Activatable Constructs - The current invention relates to a construct, a polynucleotide that encodes said construct and a cell that expresses said construct. Furthermore, the current invention relates to the use of said construct for the treatment of bleedings and their associated co-morbidities and to a method of treatment of bleedings, inflammation and metastasis of cancer cells. | 02-28-2013 |
20130211050 | ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) - The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease. | 08-15-2013 |
20130309239 | ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) - The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease. | 11-21-2013 |
20130330360 | ANTAGONISTIC DR3 LIGANDS - The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR | 12-12-2013 |
20130336984 | ANTAGONISTIC DR3 LIGANDS - The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases. | 12-19-2013 |
20140294853 | ANTAGONISTIC DR3 LIGANDS - The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases. | 10-02-2014 |
20150274825 | Antibodies that Bind and Block Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) - The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease. | 10-01-2015 |